genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Immunomodulation therapy
Featured
Stem Cell Therapies Considered Interchangeable Contain Different Cell Types
News
Macrophages May Contribute to Heartbeat Irregularities
Drug Discovery
SARS-CoV-2 Cell Surface Nucleocapsid Protein Modulates Innate and Adaptive Host Immunity
Cancer
Potential Cancer Drug Mobilizes Immunity by Suppressing SUMOylation
Drug Discovery
Evaluating Immunomodulation Therapeutics in Translationally-Relevant Humanized Mice
Drug Discovery
Momenta and CSL Partner to Develop Fc Multimer Proteins
Industry News
Protectimmun Wins Research Funding from Janssen Biotech
Cancer
Merck & Co., Dynavax to Study Cancer Immunotherapy Combinations
News
Positive Results Reported for Biogen Idec’s Oral MS Drug in First Phase III Study
Drug Discovery
Abbott Pays Biotest $85M Up Front in Deal for Phase II mAb Against RA and Psoriasis
1
2
Page 1 of 2
Scroll Up
Scroll Up
